Kimberly Lynn Blackwell | Scholars@Duke

Kimberly Lynn Blackwell
Adjunct Professor in the Department of Medicine

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Current Appointments & Affiliations

Adjunct Professor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2018

Contact Information

Duke Box 3893, Durham, NC 27710
Room 3818 Duke South, Durham, NC 27710
black034@mc.duke.edu (919) 668-1748

Background
Education, Training, & Certifications
- Fellow in Hematology-Oncology, Medicine, Duke University 1997 - 2000
- Medical Resident, Medicine, Duke University 1994 - 1997
- M.D., Mayo School of Health Sciences 1994
Previous Appointments & Affiliations
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1994 - 2019
- Assistant Professor in Radiation Oncology, Radiation Oncology, Clinical Science Departments 2004 - 2018
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2018
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2012
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2001 - 2006
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 2000 - 2001
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2000
Recognition
In the News
- FEB 12, 2016 The News & Observer
  
  Editorial: At Duke, Biden launches a ‘moonshot’ to beat cancer
- FEB 1, 2016 NPR’s “Morning Edition
  
  A diet high in fiber may help protect against breast cancer
- SEP 29, 2015
  
  U.S. Archivist David Ferriero to Address Annual Founders’ Day Ceremony
- APR 9, 2014 Durham Herald-Sun
  
  Duke breast cancer researcher honored for Women's History Month
- OCT 22, 2013 Duke Research Blog
  
  Clinical Sciences Day: Collaboration, Mentorship Lead to Science Successes
- AUG 1, 2013 WRAL.com
  
  Komen grants $3.6 million to Duke, UNC breast cancer research
Expertise
Global Scholarship
- Research
  - China (Country)
Research
Selected Grants
- Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2024
- Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy awarded by Department of Defense 2012 - 2022
- Single cell functional dissection of tumor microenviornment-driven drug resistance awarded by National Institutes of Health 2018 - 2020
- Targeting differential apoptosis regulation in triple negative breast cancer awarded by Department of Defense 2016 - 2019
- A Phase Ib, Open-Label, Two-Arm Study Evaluating The Safety And Pharmacokinetics Of Atezolizumab (ANTI-PD-L1 Antibody) In Combination With Trastuzumab Emtansine Or With Trastuzumab And Pertuzumab In Subjects With HER2 Positive Breast Cancer awarded by F. Hoffmann-La Roche Ltd 2016 - 2018
- Examining the Role of Cholesterol Metabolites on the Estrogen Receptor Signaling Pathway awarded by Susan G. Komen Breast Cancer Foundation 2015 - 2018
- Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer awarded by Genentech, Inc. 2016 - 2018
- Enhancing Efficacy of Chemotherapy in Triple Negatiave/Basal-like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer awarded by University of California - San Francisco 2013 - 2018
- A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer awarded by Merrimack Pharmaceuticals 2016 - 2018
- Directed Chemotherapy Delivery for Leptomeningeal Metastases awarded by Minnetronix, Inc 2016 - 2017
- EISAI BREAST CANCER ADVANCED TRAINING awarded by Eisai, Inc. 2016
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Novartis Breast Cancer Practicum awarded by Novartis Pharmaceuticals Corporation 2014
- Understanding Patient Expectations of Treatment Outcomes awarded by National Institutes of Health 2009 - 2011
- Role of XIAP in Therapeutic Resistance in Inflammatory Breast Cancer awarded by Dept. of the Army -- USAMRAA 2008 - 2010
- Antiestrogenic Effects on Tumor Angiogenesis awarded by National Institutes of Health 2001 - 2006
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Vahdat, Linda T., Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, et al. “Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.” Npj Breast Cancer 7, no. 1 (May 2021): 57. https://doi.org/10.1038/s41523-021-00244-6.
    Full Text
  - Swain, Sandra M., David Miles, Sung-Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, et al. “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.” Lancet Oncol 21, no. 4 (April 2020): 519–30. https://doi.org/10.1016/S1470-2045(19)30863-0.
    Full Text Link to Item
  - Freedman, Rachel A., Rebecca S. Gelman, Nathalie Y. R. Agar, Sandro Santagata, Elizabeth C. Randall, Begoña Gimenez-Cassina Lopez, Roisin M. Connolly, et al. “Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.” Clin Breast Cancer 20, no. 2 (April 2020): 145-151.e2. https://doi.org/10.1016/j.clbc.2019.07.011.
    Full Text Link to Item
  - Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.” Ann Oncol 30, no. 11 (November 1, 2019): 1842. https://doi.org/10.1093/annonc/mdz215.
    Full Text Link to Item
  - Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.
    Full Text Link to Item
  - Zhu, Li, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, et al. “Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.” J Immunother Cancer 7, no. 1 (October 18, 2019): 265. https://doi.org/10.1186/s40425-019-0755-1.
    Full Text Link to Item
  - Yardley, Denise A., Lowell Hart, Anne Favret, Sibel Blau, Sami Diab, Donald Richards, Joseph Sparano, et al. “Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.” Clin Breast Cancer 19, no. 4 (August 2019): 268-277.e1. https://doi.org/10.1016/j.clbc.2019.02.007.
    Full Text Link to Item
  - Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.
    Full Text Link to Item
  - Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.” Ann Oncol 30, no. 6 (June 1, 2019): 1019. https://doi.org/10.1093/annonc/mdy531.
    Full Text Link to Item
  - Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.
    Full Text Open Access Copy Link to Item
  - Freedman, Rachel A., Rebecca S. Gelman, Carey K. Anders, Michelle E. Melisko, Heather A. Parsons, Anne M. Cropp, Kelly Silvestri, et al. “TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.” J Clin Oncol 37, no. 13 (May 1, 2019): 1081–89. https://doi.org/10.1200/JCO.18.01511.
    Full Text Link to Item
  - Blackwell, Kimberly L., Khalil Zaman, Shukui Qin, Katherine H. R. Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, Lori J. Goldstein, and Lori J. 202 Study Group. “Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.” Clin Breast Cancer 19, no. 2 (April 2019): 97-104.e4. https://doi.org/10.1016/j.clbc.2018.12.011.
    Full Text Link to Item
  - Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.
    Full Text Link to Item
  - Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 13. https://doi.org/10.1007/s11523-018-0614-x.
    Full Text Link to Item
  - Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
    Full Text Link to Item
  - Bardia, Aditya, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L. Blackwell, et al. “Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.” Breast Cancer Res Treat 171, no. 1 (August 2018): 111–20. https://doi.org/10.1007/s10549-018-4813-z.
    Full Text Link to Item
  - Argento, A Christine, Daniel L. Gilstrap, Scott Shofer, Kamran Mahmood, Kimberly Blackwell, and Momen M. Wahidi. “Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance.” J Bronchology Interv Pulmonol 25, no. 3 (July 2018): 176–80. https://doi.org/10.1097/LBR.0000000000000476.
    Full Text Link to Item
  - Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.” Ann Oncol 29, no. 7 (July 1, 2018): 1541–47. https://doi.org/10.1093/annonc/mdy155.
    Full Text Link to Item
  - Blackwell, Kimberly, Joseph Gligorov, Ira Jacobs, and Chris Twelves. “The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.” Clin Breast Cancer 18, no. 2 (April 2018): 95–113. https://doi.org/10.1016/j.clbc.2018.01.006.
    Full Text Link to Item
  - Harbeck, Nadia, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, and Kimberly Blackwell. “Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.” Oncologist 23, no. 4 (April 2018): 403–9. https://doi.org/10.1634/theoncologist.2017-0348.
    Full Text Link to Item
  - Blackwell, K., P. Gascon, A. Krendyukov, S. Gattu, Y. Li, and N. Harbeck. “Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.” Ann Oncol 29, no. 1 (January 1, 2018): 244–49. https://doi.org/10.1093/annonc/mdx638.
    Full Text Link to Item
  - Shammas, Ronnie L., Eugenia H. Cho, Adam D. Glener, Luke P. Poveromo, Lily R. Mundy, Rachel A. Greenup, Kimberly L. Blackwell, and Scott T. Hollenbeck. “Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.” J Am Coll Surg 225, no. 6 (December 2017): 731-739.e1. https://doi.org/10.1016/j.jamcollsurg.2017.08.023.
    Full Text Link to Item
  - Ma, Cynthia X., Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, et al. “Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.” Clin Cancer Res 23, no. 19 (October 1, 2017): 5687–95. https://doi.org/10.1158/1078-0432.CCR-17-0900.
    Full Text Link to Item
  - Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.
    Full Text Link to Item
  - Nayar, Gautam, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, and Peter E. Fecci. “Leptomeningeal disease: current diagnostic and therapeutic strategies.” Oncotarget 8, no. 42 (September 22, 2017): 73312–28. https://doi.org/10.18632/oncotarget.20272.
    Full Text Link to Item
  - Blackwell, K., P. Gascon, C. M. Jones, A. Nixon, A. Krendyukov, R. Nakov, Y. Li, and N. Harbeck. “Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.” Ann Oncol 28, no. 9 (September 1, 2017): 2272–77. https://doi.org/10.1093/annonc/mdx303.
    Full Text Link to Item
  - Harbeck, Nadia, Pere Gascon, Clyde M. Jones, Allen Nixon, Andriy Krendyukov, Roumen Nakov, Yuhan Li, and Kimberly Blackwell. “Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.” Future Oncol 13, no. 16 (July 2017): 1385–93. https://doi.org/10.2217/fon-2017-0041.
    Full Text Link to Item
  - Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, et al. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.” Lancet Oncol 18, no. 6 (June 2017): 732–42. https://doi.org/10.1016/S1470-2045(17)30312-1.
    Full Text Link to Item
  - Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, et al. “Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.” Breast Cancer Res 19, no. 1 (February 10, 2017): 18. https://doi.org/10.1186/s13058-017-0807-8.
    Full Text Link to Item
  - Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.” Curr Cancer Drug Targets 17, no. 7 (2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.
    Full Text Link to Item
  - Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, et al. “PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.” Sci Transl Med 8, no. 369 (December 14, 2016): 369ra175. https://doi.org/10.1126/scitranslmed.aae0348.
    Full Text Open Access Copy Link to Item
  - Mitri, Zahi, Rita Nanda, Kimberly Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, et al. “TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.” Clin Cancer Res 22, no. 23 (December 1, 2016): 5706–12. https://doi.org/10.1158/1078-0432.CCR-15-2845.
    Full Text Link to Item
  - Hortobagyi, Gabriel N., Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Shani Paluch-Shimon, Mario Campone, et al. “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.” N Engl J Med 375, no. 18 (November 3, 2016): 1738–48. https://doi.org/10.1056/NEJMoa1609709.
    Full Text Link to Item
  - Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).” Annals of Oncology 27 (October 1, 2016): vi553. https://doi.org/10.1093/annonc/mdw435.03.
    Full Text
  - Blackwell, Kimberly, Roman Donskih, C Michael Jones, Allen Nixon, Maria J. Vidal, Roumen Nakov, Pritibha Singh, Gregor Schaffar, Pere Gascón, and Nadia Harbeck. “A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.” Oncologist 21, no. 7 (July 2016): 789–94. https://doi.org/10.1634/theoncologist.2016-0011.
    Full Text Link to Item
  - Farber, S Harrison, Vadim Tsvankin, Jessica L. Narloch, Grace J. Kim, April K. S. Salama, Gordana Vlahovic, Kimberly L. Blackwell, John P. Kirkpatrick, and Peter E. Fecci. “Embracing rejection: Immunologic trends in brain metastasis.” Oncoimmunology 5, no. 7 (July 2016): e1172153. https://doi.org/10.1080/2162402X.2016.1172153.
    Full Text Link to Item
  - Harbeck, Nadia, Oleg Lipatov, Mona Frolova, Dmitry Udovitsa, Eldar Topuzov, Doina Elena Ganea-Motan, Roumen Nakov, Pritibha Singh, Anita Rudy, and Kimberly Blackwell. “Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.” Future Oncol 12, no. 11 (June 2016): 1359–67. https://doi.org/10.2217/fon-2016-0016.
    Full Text Link to Item
  - Freedman, Rachel A., Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, et al. “Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.” J Clin Oncol 34, no. 9 (March 20, 2016): 945–52. https://doi.org/10.1200/JCO.2015.63.0343.
    Full Text Link to Item
  - Harnden, Kathleen K., and Kimberly L. Blackwell. “Increased Fiber Intake Decreases Premenopausal Breast Cancer Risk.” Pediatrics 137, no. 3 (March 2016): e20154376. https://doi.org/10.1542/peds.2015-4376.
    Full Text Link to Item
  - Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, et al. “Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.” Eur Heart J 37, no. 4 (January 21, 2016): 412–22. https://doi.org/10.1093/eurheartj/ehv611.
    Full Text Link to Item
  - Blackwell, Kimberly, Howard Burris, Patricia Gomez, N. Lynn Henry, Steven Isakoff, Frank Campana, Lei Gao, Jason Jiang, Sandrine Macé, and Sara M. Tolaney. “Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.” Breast Cancer Res Treat 154, no. 2 (November 2015): 287–97. https://doi.org/10.1007/s10549-015-3615-9.
    Full Text Link to Item
  - Kimmick, Gretchen, Sara N. Edmond, Hayden B. Bosworth, Jeffrey Peppercorn, Paul K. Marcom, Kimberly Blackwell, Francis J. Keefe, and Rebecca A. Shelby. “Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.” Breast 24, no. 5 (October 2015): 630–36. https://doi.org/10.1016/j.breast.2015.06.010.
    Full Text Link to Item
  - Blackwell, K., V. Semiglazov, D. Krasnozhon, I. Davidenko, L. Nelyubina, R. Nakov, G. Stiegler, et al. “Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.” Ann Oncol 26, no. 9 (September 2015): 1948–53. https://doi.org/10.1093/annonc/mdv281.
    Full Text Link to Item
  - Siamakpour-Reihani, Sharareh, Kouros Owzar, Chen Jiang, Peter M. Scarbrough, Oana I. Craciunescu, Janet K. Horton, Holly K. Dressman, Kimberly L. Blackwell, and Mark W. Dewhirst. “Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.” Int J Hyperthermia 31, no. 4 (June 2015): 386–95. https://doi.org/10.3109/02656736.2015.1016557.
    Full Text Link to Item
  - Harnden, Kathleen, and Kimberly Blackwell. “Routine use of zoledronic acid in early-stage breast cancer.” J Natl Compr Canc Netw 13, no. 4 (April 2015): 480–86. https://doi.org/10.6004/jnccn.2015.0061.
    Full Text Link to Item
  - Krop, I. E., N. U. Lin, K. Blackwell, E. Guardino, J. Huober, M. Lu, D. Miles, M. Samant, M. Welslau, and V. Diéras. “Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.” Ann Oncol 26, no. 1 (January 2015): 113–19. https://doi.org/10.1093/annonc/mdu486.
    Full Text Link to Item
  - Spector, Neil L., Faith C. Robertson, Sarah Bacus, Kimberly Blackwell, Deborah A. Smith, Kelli Glenn, Leanne Cartee, et al. “Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.” Plos One 10, no. 11 (2015): e0142845. https://doi.org/10.1371/journal.pone.0142845.
    Full Text Link to Item
  - Burstein, Harold J., Constance T. Cirrincione, William T. Barry, Helen K. Chew, Sara M. Tolaney, Diana E. Lake, Cynthia Ma, Kimberly L. Blackwell, Eric P. Winer, and Clifford A. Hudis. “Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).” J Clin Oncol 32, no. 35 (December 10, 2014): 3959–66. https://doi.org/10.1200/JCO.2014.56.7941.
    Full Text Link to Item
  - Cardoso, F., A. Costa, L. Norton, E. Senkus, M. Aapro, F. André, C. H. Barrios, et al. “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.” Ann Oncol 25, no. 10 (October 2014): 1871–88. https://doi.org/10.1093/annonc/mdu385.
    Full Text Link to Item
  - Cardoso, F., A. Costa, L. Norton, E. Senkus, M. Aapro, F. André, C. H. Barrios, et al. “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).” Breast 23, no. 5 (October 2014): 489–502. https://doi.org/10.1016/j.breast.2014.08.009.
    Full Text Link to Item
  - Shelby, Rebecca A., Sara N. Edmond, Anava A. Wren, Francis J. Keefe, Jeffrey M. Peppercorn, Paul K. Marcom, Kimberly L. Blackwell, and Gretchen G. Kimmick. “Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.” Support Care Cancer 22, no. 10 (October 2014): 2851–59. https://doi.org/10.1007/s00520-014-2269-1.
    Full Text Link to Item
  - Tripathy, Debu, Kathleen Harnden, Kimberly Blackwell, and Mark Robson. “Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?” Bmc Med 12 (August 12, 2014): 140. https://doi.org/10.1186/s12916-014-0140-3.
    Full Text Link to Item
  - Zagar, Timothy M., Zeljko Vujaskovic, Silvia Formenti, Hope Rugo, Franco Muggia, Brigid O’Connor, Robert Myerson, et al. “Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.” Int J Hyperthermia 30, no. 5 (August 2014): 285–94. https://doi.org/10.3109/02656736.2014.936049.
    Full Text Link to Item
  - Aapro, M., F. Andre, K. Blackwell, E. Calvo, M. Jahanzeb, K. Papazisis, C. Porta, K. Pritchard, and A. Ravaud. “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.” Ann Oncol 25, no. 4 (April 2014): 763–73. https://doi.org/10.1093/annonc/mdu021.
    Full Text Link to Item
  - Malin, Dmitry, Elena Strekalova, Vladimir Petrovic, Allison M. Deal, Abraham Al Ahmad, Barbara Adamo, C Ryan Miller, et al. “αB-crystallin: a novel regulator of breast cancer metastasis to the brain.” Clin Cancer Res 20, no. 1 (January 1, 2014): 56–67. https://doi.org/10.1158/1078-0432.CCR-13-1255.
    Full Text Link to Item
  - Hamilton, Erika, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, and Kimberly Blackwell. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.” Clin Breast Cancer 13, no. 6 (December 2013): 416–20. https://doi.org/10.1016/j.clbc.2013.08.003.
    Full Text Link to Item
  - Gucalp, Ayca, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, et al. “Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.” Clin Cancer Res 19, no. 19 (October 1, 2013): 5505–12. https://doi.org/10.1158/1078-0432.CCR-12-3327.
    Full Text Link to Item
  - Jones, Lee W., Diane R. Fels, Miranda West, Jason D. Allen, Gloria Broadwater, William T. Barry, Lee G. Wilke, et al. “Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.” Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925–37. https://doi.org/10.1158/1940-6207.CAPR-12-0416.
    Full Text Link to Item
  - Hamilton, E. P., and K. L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?” Oncology (Williston Park, N.Y.) 27, no. 3 (March 1, 2013).
  - Hamilton, Erika P., and Kimberly L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?” Oncology (Williston Park) 27, no. 3 (March 2013): 180–82.
    Link to Item
  - Blackwell, K. L. “An option after pertuzumab and TDM-1.” Oncology Report, no. AUG (January 1, 2013): 3.
  - Cristofanilli, M., S. R. D. Johnston, A. Manikhas, H. L. Gomez, O. Gladkov, Z. Shao, S. Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.” Breast Cancer Research and Treatment 137, no. 2 (2013): 471–82. https://doi.org/10.1007/s10549-012-2369-x.
    Full Text
  - Cristofanilli, Massimo, Stephen R. D. Johnston, Alexey Manikhas, Henry L. Gomez, Oleg Gladkov, Zhimin Shao, Sufia Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.” Breast Cancer Res Treat 137, no. 2 (January 2013): 471–82. https://doi.org/10.1007/s10549-012-2369-x.
    Full Text Link to Item
  - Verma, Sunil, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark Pegram, et al. “Trastuzumab emtansine for HER2-positive advanced breast cancer.” N Engl J Med 367, no. 19 (November 8, 2012): 1783–91. https://doi.org/10.1056/NEJMoa1209124.
    Full Text Link to Item
  - Roe, Matthew T., Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, et al. “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.” N Engl J Med 367, no. 14 (October 4, 2012): 1297–1309. https://doi.org/10.1056/NEJMoa1205512.
    Full Text Link to Item
  - Blackwell, Kimberly L., Harold J. Burstein, Anna Maria Storniolo, Hope S. Rugo, George Sledge, Gursel Aktan, Catherine Ellis, et al. “Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.” J Clin Oncol 30, no. 21 (July 20, 2012): 2585–92. https://doi.org/10.1200/JCO.2011.35.6725.
    Full Text Link to Item
  - Ren, Xiu-Rong, Junping Wei, Gangjun Lei, Jiangbo Wang, Jiuyi Lu, Wenle Xia, Neil Spector, et al. “Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.” Breast Cancer Res 14, no. 3 (June 7, 2012): R89. https://doi.org/10.1186/bcr3204.
    Full Text Link to Item
  - Betof, A. S., Z. N. Rabbani, M. E. Hardee, S. J. Kim, G. Broadwater, R. C. Bentley, S. A. Snyder, et al. “Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.” Br J Cancer 106, no. 5 (February 28, 2012): 916–22. https://doi.org/10.1038/bjc.2012.32.
    Full Text Link to Item
  - Hamilton, Erika, Kimberly Blackwell, Amy C. Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, et al. “Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].” J Transl Med 10 (February 10, 2012): 28. https://doi.org/10.1186/1479-5876-10-28.
    Full Text Link to Item
  - Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.” Ann Oncol 22, no. 12 (December 2011): 2582–90. https://doi.org/10.1093/annonc/mdr014.
    Full Text Link to Item
  - Hamilton, Erika, Timothy M. Clay, and Kimberly L. Blackwell. “New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.” Cancer Invest 29, no. 8 (October 2011): 533–41. https://doi.org/10.3109/07357907.2011.605413.
    Full Text Link to Item
  - Herold, Christina I., Vijaya Chadaram, Bercedis L. Peterson, P Kelly Marcom, Judith Hopkins, Gretchen G. Kimmick, Justin Favaro, et al. “Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.” Clin Cancer Res 17, no. 18 (September 15, 2011): 6061–70. https://doi.org/10.1158/1078-0432.CCR-11-1071.
    Full Text Link to Item
  - Xia, Wenle, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, et al. “Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.” Mol Cancer Ther 10, no. 8 (August 2011): 1367–74. https://doi.org/10.1158/1535-7163.MCT-10-0991.
    Full Text Link to Item
  - Morse, Michael A., Robert Chapman, John Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, et al. “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.” Clin Cancer Res 17, no. 14 (July 15, 2011): 4844–53. https://doi.org/10.1158/1078-0432.CCR-11-0891.
    Full Text Link to Item
  - Gatza, Michael L., Hsiu-Ni Kung, Kimberly L. Blackwell, Mark W. Dewhirst, Jeffrey R. Marks, and Jen-Tsan Chi. “Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.” Breast Cancer Res 13, no. 3 (June 7, 2011): R62. https://doi.org/10.1186/bcr2899.
    Full Text Link to Item
  - Morse, Michael A., Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, et al. “MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.” Clin Cancer Res 17, no. 10 (May 15, 2011): 3408–19. https://doi.org/10.1158/1078-0432.CCR-10-2614.
    Full Text Link to Item
  - Adamo, Barbara, Allison M. Deal, Emily Burrows, Joseph Geradts, Erika Hamilton, Kimberly L. Blackwell, Chad Livasy, et al. “Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.” Breast Cancer Res 13, no. 6 (2011): R125. https://doi.org/10.1186/bcr3071.
    Full Text Link to Item
  - Anders, Carey K., Cheng Fan, Joel S. Parker, Lisa A. Carey, Kimberly L. Blackwell, Nancy Klauber-DeMore, and Charles M. Perou. “Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?” J Clin Oncol 29, no. 1 (January 1, 2011): e18–20. https://doi.org/10.1200/JCO.2010.28.9199.
    Full Text Link to Item
  - Hamilton, Erika P., and Kimberly L. Blackwell. “Safety of bevacizumab in patients with metastatic breast cancer.” Oncology 80, no. 5–6 (2011): 314–25. https://doi.org/10.1159/000328757.
    Full Text Link to Item
  - Hamilton, E. P., and K. L. Blackwell. “Third-generation aromatase inhibitors: Differences between the agents and their role in reducing the risk of distant metastasis and improving survival.” European Journal of Clinical and Medical Oncology 2, no. 4 (December 1, 2010).
  - Mouridsen, Henning T., Per Lønning, Matthias W. Beckmann, Kimberly Blackwell, Julie Doughty, Joseph Gligorov, Antonio Llombart-Cussac, Andre Robidoux, Beat Thürlimann, and Michael Gnant. “Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.” Expert Rev Anticancer Ther 10, no. 11 (November 2010): 1825–36. https://doi.org/10.1586/era.10.160.
    Full Text Link to Item
  - Spector, N. L., and K. L. Blackwell. “Reply to F. Bellati et al.” Journal of Clinical Oncology 28, no. 21 (July 20, 2010). https://doi.org/10.1200/JCO.2010.28.8571.
    Full Text
  - Russell, Stuart D., Kimberly L. Blackwell, Julia Lawrence, John E. Pippen, Matthew T. Roe, Freda Wood, Virginia Paton, Eric Holmgren, and Kenneth W. Mahaffey. “Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.” J Clin Oncol 28, no. 21 (July 20, 2010): 3416–21. https://doi.org/10.1200/JCO.2009.23.6950.
    Full Text Link to Item
  - Blackwell, Kimberly L., Harold J. Burstein, Anna Maria Storniolo, Hope Rugo, George Sledge, Maria Koehler, Catherine Ellis, et al. “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.” J Clin Oncol 28, no. 7 (March 1, 2010): 1124–30. https://doi.org/10.1200/JCO.2008.21.4437.
    Full Text Link to Item
  - Vujaskovic, Zeljko, Dong W. Kim, Ellen Jones, Lan Lan, Linda McCall, Mark W. Dewhirst, Oana Craciunescu, et al. “A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.” Int J Hyperthermia 26, no. 5 (2010): 514–21. https://doi.org/10.3109/02656731003639364.
    Full Text Link to Item
  - Zagar, Timothy M., James R. Oleson, Zeljko Vujaskovic, Mark W. Dewhirst, Oana I. Craciunescu, Kimberly L. Blackwell, Leonard R. Prosnitz, and Ellen L. Jones. “Hyperthermia for locally advanced breast cancer.” Int J Hyperthermia 26, no. 7 (2010): 618–24. https://doi.org/10.3109/02656736.2010.501051.
    Full Text Link to Item
  - Zagar, Timothy M., James R. Oleson, Zeljko Vujaskovic, Mark W. Dewhirst, Oana I. Craciunescu, Kimberly L. Blackwell, Leonard R. Prosnitz, and Ellen L. Jones. “Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.” Int J Hyperthermia 26, no. 7 (2010): 612–17. https://doi.org/10.3109/02656736.2010.487194.
    Full Text Link to Item
  - Grunberg, S. M., J. Weeks, W. F. Magnan, J. Herndon, M. L. Naughton, K. L. Blackwell, M. E. Wood, et al. “Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801.” Journal of Supportive Oncology 7, no. 5 (December 1, 2009).
  - Spector, Neil L., and Kimberly L. Blackwell. “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.” J Clin Oncol 27, no. 34 (December 1, 2009): 5838–47. https://doi.org/10.1200/JCO.2009.22.1507.
    Full Text Link to Item
  - Westmoreland, Tammy J., Sajith M. Wickramasekara, Andrew Y. Guo, Alice L. Selim, Tiffany S. Winsor, Arno L. Greenleaf, Kimberly L. Blackwell, John A. Olson, Jeffrey R. Marks, and Craig B. Bennett. “Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae.” Plos One 4, no. 6 (June 8, 2009): e5830. https://doi.org/10.1371/journal.pone.0005830.
    Full Text Link to Item
  - Blackwell, K. L., M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein. “Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.” Ann Oncol 20, no. 6 (June 2009): 1026–31. https://doi.org/10.1093/annonc/mdn759.
    Full Text Link to Item
  - Kaufman, Bella, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, et al. “Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.” Lancet Oncol 10, no. 6 (June 2009): 581–88. https://doi.org/10.1016/S1470-2045(09)70087-7.
    Full Text Link to Item
  - Lacouture, M. E., S. M. Laabs, M. Koehler, R. W. Sweetman, A. J. Preston, A. Di Leo, H. L. Gomez, et al. “Analysis of dermatologic events in patients with cancer treated with lapatinib.” Breast Cancer Res Treat 114, no. 3 (April 2009): 485–93. https://doi.org/10.1007/s10549-008-0020-7.
    Full Text Link to Item
  - Craciunescu, Oana I., Kimberly L. Blackwell, Ellen L. Jones, James R. Macfall, Daohai Yu, Zeljko Vujaskovic, Terence Z. Wong, et al. “DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.” Int J Hyperthermia 25, no. 6 (2009): 405–15. https://doi.org/10.1080/02656730903022700.
    Full Text Link to Item
  - Hardee, Matthew E., Rose J. Eapen, Zahid N. Rabbani, Matthew R. Dreher, Jeffrey Marks, Kimberly L. Blackwell, and Mark W. Dewhirst. “Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.” Cancer Chemother Pharmacol 63, no. 2 (January 2009): 219–28. https://doi.org/10.1007/s00280-008-0729-3.
    Full Text Link to Item
  - Nunes, Raquel A., Xiaochun Li, Soonmo Peter Kang, Harold Burstein, Lisa Roberts, Walter Carney, Kimberly Blackwell, et al. “Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.” Int J Biol Markers 24, no. 1 (2009): 1–10. https://doi.org/10.1177/172460080902400101.
    Full Text Link to Item
  - Anders, C., P. K. Marcom, B. Peterson, L. Gu, S. Unruhe, R. Welch, P. Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer (Cancer Investigation 26, 3, (286-295)).” Cancer Investigation 26, no. 10 (December 1, 2008): 1068. https://doi.org/10.1080/07357900802660220.
    Full Text
  - Blackwell, Kimberly L. “Are all aromatase inhibitors alike?” Breast Cancer Res Treat 112 Suppl 1 (December 2008): 35–43. https://doi.org/10.1007/s10549-008-0233-9.
    Full Text Link to Item
  - Anders, Carey K., David S. Hsu, Gloria Broadwater, Chaitanya R. Acharya, John A. Foekens, Yi Zhang, Yixin Wang, et al. “Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.” J Clin Oncol 26, no. 20 (July 10, 2008): 3324–30. https://doi.org/10.1200/JCO.2007.14.2471.
    Full Text Link to Item
  - Burstein, H. J., A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell. “A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.” Ann Oncol 19, no. 6 (June 2008): 1068–74. https://doi.org/10.1093/annonc/mdm601.
    Full Text Link to Item
  - Bullock, Karen, and Kimberly Blackwell. “Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.” Oncologist 13, no. 5 (May 2008): 515–25. https://doi.org/10.1634/theoncologist.2007-0204.
    Full Text Link to Item
  - Johnston, Stephen, Maureen Trudeau, Bella Kaufman, Hamouda Boussen, Kimberley Blackwell, Patricia LoRusso, Donald P. Lombardi, et al. “Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.” J Clin Oncol 26, no. 7 (March 1, 2008): 1066–72. https://doi.org/10.1200/JCO.2007.13.9949.
    Full Text Link to Item
  - Herold, Christina I., and Kimberly L. Blackwell. “Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.” Clin Breast Cancer 8, no. 1 (February 2008): 50–64. https://doi.org/10.3816/CBC.2008.n.003.
    Full Text Link to Item
  - Demark-Wahnefried, Wendy, L Douglas Case, Kimberly Blackwell, P Kelly Marcom, William Kraus, Noreen Aziz, Denise Clutter Snyder, Jeffrey K. Giguere, and Edward Shaw. “Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy.” Clin Breast Cancer 8, no. 1 (February 2008): 70–79. https://doi.org/10.3816/CBC.2008.n.005.
    Full Text Link to Item
  - Anders, Carey K., Chaitanya R. Acharya, David S. Hsu, Gloria Broadwater, Katherine Garman, John A. Foekens, Yi Zhang, et al. “Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.” Plos One 3, no. 1 (January 2, 2008): e1373. https://doi.org/10.1371/journal.pone.0001373.
    Full Text Open Access Copy Link to Item
  - Blackwell, K. L. “The significance of distant metastases in breast cancer.” Breast (Edinburgh, Scotland) 17 Suppl 1 (January 1, 2008).
  - Blackwell, Kimberly L. “The significance of distant metastases in breast cancer.” Breast 17 Suppl 1 (January 2008): S1–2. https://doi.org/10.1016/S0960-9776(08)70001-8.
    Full Text Link to Item
  - Nolen, Brian M., Jeffrey R. Marks, Shlomo Ta’san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, and Anna E. Lokshin. “Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.” Breast Cancer Res 10, no. 3 (2008): R45. https://doi.org/10.1186/bcr2096.
    Full Text Link to Item
  - Anders, Carey, P Kelly Marcom, Bercedis Peterson, Lin Gu, Sue Unruhe, Renee Welch, Peggy Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.” Cancer Invest 26, no. 3 (2008): 286–95. https://doi.org/10.1080/07357900701829777.
    Full Text Link to Item
  - Herold, Christina I., and Kimberly L. Blackwell. “The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.” Breast 17 Suppl 1 (January 2008): S15–24. https://doi.org/10.1016/S0960-9776(08)70004-3.
    Full Text Link to Item
  - Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.” J Transl Med 5 (September 6, 2007): 42. https://doi.org/10.1186/1479-5876-5-42.
    Full Text Link to Item
  - Hardee, Matthew E., Zahid N. Rabbani, Murat O. Arcasoy, John P. Kirkpatrick, Zeljko Vujaskovic, Mark W. Dewhirst, and Kimberly L. Blackwell. “Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.” Mol Cancer Ther 5, no. 2 (February 2006): 356–61. https://doi.org/10.1158/1535-7163.MCT-05-0196.
    Full Text Link to Item
  - Kirkpatrick, John P., Matthew E. Hardee, Stacey A. Snyder, Catherine M. Peltz, Yulin Zhao, David M. Brizel, Mark W. Dewhirst, and Kimberly L. Blackwell. “The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma.” Radiat Res 165, no. 2 (February 2006): 192–201. https://doi.org/10.1667/rr3499.1.
    Full Text Link to Item
  - Dressman, Holly K., Christopher Hans, Andrea Bild, John A. Olson, Eric Rosen, P Kelly Marcom, Vlayka B. Liotcheva, et al. “Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 819–26. https://doi.org/10.1158/1078-0432.CCR-05-1447.
    Full Text Link to Item
  - Hardee, Matthew E., Murat O. Arcasoy, Kimberly L. Blackwell, John P. Kirkpatrick, and Mark W. Dewhirst. “Erythropoietin biology in cancer.” Clin Cancer Res 12, no. 2 (January 15, 2006): 332–39. https://doi.org/10.1158/1078-0432.CCR-05-1771.
    Full Text Link to Item
  - Hardee, M. E., J. P. Kirkpatrick, S. Shan, S. A. Snyder, Z. Vujaskovic, Z. N. Rabbani, M. W. Dewhirst, and K. L. Blackwell. “Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis.” Br J Cancer 93, no. 12 (December 12, 2005): 1350–55. https://doi.org/10.1038/sj.bjc.6602846.
    Full Text Link to Item
  - Burris, Howard A., Herbert I. Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O’Neil, Paul K. Marcom, et al. “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.” J Clin Oncol 23, no. 23 (August 10, 2005): 5305–13. https://doi.org/10.1200/JCO.2005.16.584.
    Full Text Link to Item
  - Spector, Neil L., Wenle Xia, Howard Burris, Herbert Hurwitz, E Claire Dees, Afshin Dowlati, Bert O’Neil, et al. “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.” J Clin Oncol 23, no. 11 (April 10, 2005): 2502–12. https://doi.org/10.1200/JCO.2005.12.157.
    Full Text Link to Item
  - Chu, Isabel, Kimberly Blackwell, Susie Chen, and Joyce Slingerland. “The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.” Cancer Res 65, no. 1 (January 1, 2005): 18–25.
    Link to Item
  - Daniel, B. R., and K. Blackwell. “Ectopic breast cancer: Rare, treatable, and potentially curable.” Community Oncology 2, no. 2 (January 1, 2005): 120–22. https://doi.org/10.1016/S1548-5315(11)70864-6.
    Full Text
  - Craciunescu, O. I., E. L. Jones, K. L. Blackwell, T. Z. Wong, E. L. Rosen, Z. Vujaskovic, J. R. MacFall, et al. “Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamic-enhanced magnetic resonance imaging (DE-MRI).” Proc. Spie Int. Soc. Opt. Eng. (Usa) 5698, no. 1 (2005): 116–25. https://doi.org/10.1117/12.591173.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Robyn Sayer, Stacey A. Snyder, Gloria Broadwater, Gustavo C. Rodriguez, Andrew Berchuck, and Kimberly Blackwell. “The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.” Gynecol Oncol 94, no. 1 (July 2004): 74–79. https://doi.org/10.1016/j.ygyno.2004.03.043.
    Full Text Link to Item
  - Rosen, E. L., K. L. Blackwell, J. A. Baker, and S. G. Orel. “Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.” Breast Diseases 15, no. 2 (July 1, 2004): 140–42.
  - Blackwell, Kimberly, Herbert Hurwitz, Grazyna Liebérman, William Novotny, Stacey Snyder, Mark Dewhirst, and Charles Greenberg. “Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.” Cancer 101, no. 1 (July 1, 2004): 77–82. https://doi.org/10.1002/cncr.20336.
    Full Text Link to Item
  - Blackwell, Kimberly L., Mark W. Dewhirst, Vlayka Liotcheva, Stacey Snyder, Gloria Broadwater, Rex Bentley, Anita Lal, et al. “HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.” Clin Cancer Res 10, no. 12 Pt 1 (June 15, 2004): 4083–88. https://doi.org/10.1158/1078-0432.CCR-03-0695.
    Full Text Link to Item
  - Blackwell, Kimberly, Pere Gascón, George Sigounas, and Linda Jolliffe. “rHuEPO and improved treatment outcomes: potential modes of action.” Oncologist 9 Suppl 5 (2004): 41–47. https://doi.org/10.1634/theoncologist.9-90005-41.
    Full Text Link to Item
  - Harrison, Louis, and Kimberly Blackwell. “Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?” Oncologist 9 Suppl 5 (2004): 31–40. https://doi.org/10.1634/theoncologist.9-90005-31.
    Full Text Link to Item
  - Rosen, Eric L., Kimberly L. Blackwell, Jay A. Baker, Mary Scott Soo, Rex C. Bentley, Daohai Yu, Thaddeus V. Samulski, and Mark W. Dewhirst. “Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.” Ajr Am J Roentgenol 181, no. 5 (November 2003): 1275–82. https://doi.org/10.2214/ajr.181.5.1811275.
    Full Text Link to Item
  - Blackwell, Kimberly L., John P. Kirkpatrick, Stacey A. Snyder, Gloria Broadwater, Francis Farrell, Linda Jolliffe, David M. Brizel, and Mark W. Dewhirst. “Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin.” Cancer Res 63, no. 19 (October 1, 2003): 6162–65.
    Link to Item
  - Vujaskovic, Z., E. L. Rosen, K. L. Blackwell, E. L. Jones, D. M. Brizel, L. R. Prosnitz, T. V. Samulski, and M. W. Dewhirst. “Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment.” Int J Hyperthermia 19, no. 5 (2003): 498–506. https://doi.org/10.1080/0265673031000121517.
    Full Text Link to Item
  - Weber, R. S., E. Abemayor, G. L. Adams, D. J. Adelstein, A. Alavi, E. Alford, M. Al-Sarraf, et al. “Head and neck: Editorial.” Head and Neck 23, no. 12 (December 13, 2001): 1021–23. https://doi.org/10.1002/hed.1148.
    Full Text
  - Demark-Wahnefried, W., B. L. Peterson, E. P. Winer, L. Marks, N. Aziz, P. K. Marcom, K. Blackwell, and B. K. Rimer. “Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.” J Clin Oncol 19, no. 9 (May 1, 2001): 2381–89. https://doi.org/10.1200/JCO.2001.19.9.2381.
    Full Text Link to Item
  - Blackwell, K. L., Z. A. Haroon, S. Shan, W. Saito, G. Broadwater, C. S. Greenberg, and M. W. Dewhirst. “Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.” Clin Cancer Res 6, no. 11 (November 2000): 4359–64.
    Link to Item
  - Blackwell, K., Z. Haroon, G. Broadwater, D. Berry, L. Harris, J. D. Iglehart, M. Dewhirst, and C. Greenberg. “Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status.” J Clin Oncol 18, no. 3 (February 2000): 600–608. https://doi.org/10.1200/JCO.2000.18.3.600.
    Full Text Link to Item
  - Blackwell, K. L., D. G. Bostwick, R. P. Myers, H. Zincke, and J. E. Oesterling. “Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.” J Urol 151, no. 6 (June 1994): 1565–70. https://doi.org/10.1016/s0022-5347(17)35303-x.
    Full Text Link to Item
  - Sandok, B. A., R. R. Orford, and K. L. Blackwell. “A clinical experience in social medicine/cultural diversity.” Acad Med 69, no. 5 (May 1994): 410–11.
    Link to Item
  - Secord, A. A., R. Sayer, S. A. Snyder, G. Broadwater, G. C. Rodriguez, A. Berchuck, and K. Blackwell. “Second-look laparotomy in ovarian cancer.” Gynecologic Oncology 55, no. 3 (January 1, 1994): S122–27. https://doi.org/10.1006/gyno.1994.1350.
    Full Text
- Book Sections
  - Sammons, S., and K. Blackwell. “HER2-positive breast cancer.” In HER2-Positive Breast Cancer, 63–74, 2018. https://doi.org/10.1016/B978-0-323-58122-6.00004-0.
    Full Text
  - Verrier, C. S., and K. Blackwell. “Is rhere a role for ErbB dual kinase inhibition?” In Breast Cancer: Translational Therapeutic Strategies, 203–12, 2007.
- Other Articles
  - Hamilton, E., K. Blackwell, A. C. Hobeika, T. M. Clay, G. Broadwater, X. R. Ren, W. Chen, et al. “Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.” J Transl Med, 2013. https://doi.org/10.1186/1479-5876-11-82.
    Full Text Link to Item
- Conference Papers
  - Schmid, P., M. Melisko, D. A. Yardley, K. Blackwell, A. Forero, G. Ouellette, Y. He, R. G. Bagley, J. Zhang, and L. T. Vahdat. “METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC).” In Annals of Oncology, 27:vi97, 2016. https://doi.org/10.1093/annonc/mdw365.88.
    Full Text
  - Craciunescu, O., T. Raidy, D. Brizel, K. Blackwell, Z. Vujaskovic, T. Wong, E. Jones, N. Larrier, J. Macfall, and M. Dewhirst. “SU‐FF‐J‐125: Therapy Assessment Using a Full Time Point (fTP) Pharmacokinetic Analysis of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging (DCE‐MRI): Role of Region of Interest (ROI) Selection in Three Tumor Sites.” In Medical Physics, 33:2049, 2006. https://doi.org/10.1118/1.2240901.
    Full Text
  - Craciunescu, O., K. Blackwell, T. Wong, E. Rosen, T. Raidy, E. Jones, Z. Vujaskovic, et al. “SU‐EE‐A2‐06: Non‐Contact, Non‐Invasive Breast Thermography Has Potential to Evaluate Treatment Response in Breast Cancer Patients.” In Medical Physics, 32:1898, 2005. https://doi.org/10.1118/1.1997458.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

In the News

Global Scholarship

Research

Selected Grants

Selected Publications

Academic Articles

Book Sections

Other Articles

Conference Papers